Design and Evaluation of Cryptolepine Hydrochloride-Loaded Gelatine Nanoparticles Intended for Parenteral Administration
0 sources
Design and Evaluation of Cryptolepine Hydrochloride-Loaded Gelatine Nanoparticles Intended for Parenteral Administration
Summary
Design and Evaluation of Cryptolepine Hydrochloride-Loaded Gelatine Nanoparticles Intended for Parenteral Administration is a doctoral thesis[1].
Key Facts
- Design and Evaluation of Cryptolepine Hydrochloride-Loaded Gelatine Nanoparticles Intended for Parenteral Administration authored Noble Kuntworbe[2].
- Design and Evaluation of Cryptolepine Hydrochloride-Loaded Gelatine Nanoparticles Intended for Parenteral Administration's instance of is recorded as doctoral thesis[3].
- Design and Evaluation of Cryptolepine Hydrochloride-Loaded Gelatine Nanoparticles Intended for Parenteral Administration's publisher is recorded as ResearchSpace@Auckland[4].
- Design and Evaluation of Cryptolepine Hydrochloride-Loaded Gelatine Nanoparticles Intended for Parenteral Administration's copyright license is recorded as Creative Commons Attribution-NonCommercial-ShareAlike 3.0 New Zealand[5].
- Design and Evaluation of Cryptolepine Hydrochloride-Loaded Gelatine Nanoparticles Intended for Parenteral Administration's country of origin is recorded as New Zealand[6].
- Design and Evaluation of Cryptolepine Hydrochloride-Loaded Gelatine Nanoparticles Intended for Parenteral Administration's publication date is recorded as +2012-00-00T00:00:00Z[7].
- Design and Evaluation of Cryptolepine Hydrochloride-Loaded Gelatine Nanoparticles Intended for Parenteral Administration's work available at URL is recorded as https://researchspace.auckland.ac.nz/handle/2292/19487[8].
- Design and Evaluation of Cryptolepine Hydrochloride-Loaded Gelatine Nanoparticles Intended for Parenteral Administration's Handle ID is recorded as 2292/19487[9].
- Design and Evaluation of Cryptolepine Hydrochloride-Loaded Gelatine Nanoparticles Intended for Parenteral Administration's title is recorded as Design and Evaluation of Cryptolepine Hydrochloride-Loaded Gelatine Nanoparticles Intended for Parenteral Administration[10].
- Design and Evaluation of Cryptolepine Hydrochloride-Loaded Gelatine Nanoparticles Intended for Parenteral Administration's copyright holder is recorded as Noble Kuntworbe[11].
- Design and Evaluation of Cryptolepine Hydrochloride-Loaded Gelatine Nanoparticles Intended for Parenteral Administration's thesis submitted to is recorded as University of Auckland[12].
- Design and Evaluation of Cryptolepine Hydrochloride-Loaded Gelatine Nanoparticles Intended for Parenteral Administration's on focus list of Wikimedia project is recorded as NZThesisProject[13].
- Design and Evaluation of Cryptolepine Hydrochloride-Loaded Gelatine Nanoparticles Intended for Parenteral Administration's copyright status is recorded as copyrighted[14].
- Design and Evaluation of Cryptolepine Hydrochloride-Loaded Gelatine Nanoparticles Intended for Parenteral Administration's online access status is recorded as open access[15].
- Design and Evaluation of Cryptolepine Hydrochloride-Loaded Gelatine Nanoparticles Intended for Parenteral Administration's thesis committee member is recorded as Margaret Brimble[16].
- Design and Evaluation of Cryptolepine Hydrochloride-Loaded Gelatine Nanoparticles Intended for Parenteral Administration's thesis committee member is recorded as Raid Ghassan Alany[17].
- Design and Evaluation of Cryptolepine Hydrochloride-Loaded Gelatine Nanoparticles Intended for Parenteral Administration's thesis committee member is recorded as Raida Al-Kassas[18].
- Design and Evaluation of Cryptolepine Hydrochloride-Loaded Gelatine Nanoparticles Intended for Parenteral Administration's thesis committee member is recorded as Nataly Martini[19].
Body
Designation and Status
Design and Evaluation of Cryptolepine Hydrochloride-Loaded Gelatine Nanoparticles Intended for Parenteral Administration's instance of is recorded as doctoral thesis[3].